ketoconazole has been researched along with Breast Neoplasms in 13 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Breast Neoplasms: Tumors or cancer of the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared cycle 1 docetaxel pharmacokinetics and pharmacodynamics between ketoconazole-modulated (70 mg flat-dose docetaxel, n = 31) and conventional-dosed docetaxel (75 mg/m², n = 51) in chemonaive breast cancer patients in two sequential phase II studies." | 9.14 | Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. ( Buhari, SA; Chan, CW; Chuah, BYS; Cordero, MT; Goh, BC; Iau, P; Lee, SC; Lim, SE; Lim, YW; Soo, R; Sukri, NB; Tan, SH; Wang, LZ, 2010) |
| "The effects of aminoglutethimide, econazole and ketoconazole on human breast cancer cells in culture were compared with those of tamoxifen using four methods (growth experiments, thymidine incorporation, monoparameter and bivariate DNA content flow cytometry analysis)." | 7.68 | Comparative studies of steroidogenesis inhibitors (econazole, ketoconazole) on human breast cancer MCF-7 cell proliferation by growth experiments, thymidine incorporation and flow cytometric DNA analysis. ( Najid, A; Ratinaud, MH, 1991) |
| "Ketoconazole was poorly tolerated due to gastrointestinal toxicity." | 5.27 | High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer. ( Cantwell, BM; Dowsett, M; Harris, AL, 1988) |
| "We compared cycle 1 docetaxel pharmacokinetics and pharmacodynamics between ketoconazole-modulated (70 mg flat-dose docetaxel, n = 31) and conventional-dosed docetaxel (75 mg/m², n = 51) in chemonaive breast cancer patients in two sequential phase II studies." | 5.14 | Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients. ( Buhari, SA; Chan, CW; Chuah, BYS; Cordero, MT; Goh, BC; Iau, P; Lee, SC; Lim, SE; Lim, YW; Soo, R; Sukri, NB; Tan, SH; Wang, LZ, 2010) |
| "The growth-inhibitory effects of ketoconazole, an antifungal agent which inhibits arachidonic acid lipoxygenases and cytochrome P-450 enzymes, were tested in human colon and breast cancer cell lines." | 3.68 | Effects of ketoconazole on the proliferation and cell cycle of human cancer cell lines. ( Coudray, AM; Fagot, D; Forgue-Lafitte, ME; Mester, J, 1992) |
| "The effects of aminoglutethimide, econazole and ketoconazole on human breast cancer cells in culture were compared with those of tamoxifen using four methods (growth experiments, thymidine incorporation, monoparameter and bivariate DNA content flow cytometry analysis)." | 3.68 | Comparative studies of steroidogenesis inhibitors (econazole, ketoconazole) on human breast cancer MCF-7 cell proliferation by growth experiments, thymidine incorporation and flow cytometric DNA analysis. ( Najid, A; Ratinaud, MH, 1991) |
| "About one third of patients with breast cancer show objective improvement with aminoglutethimide, and it may also be of use in the treatment of adrenal carcinoma." | 2.37 | Aminoglutethimide and ketoconazole: historical perspectives and future prospects. ( Nicholls, PJ; Shaw, MA; Smith, HJ, 1988) |
| "Ketoconazole was poorly tolerated due to gastrointestinal toxicity." | 1.27 | High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer. ( Cantwell, BM; Dowsett, M; Harris, AL, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (46.15) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 2 (15.38) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patel, JB | 1 |
| Huynh, CK | 1 |
| Handratta, VD | 1 |
| Gediya, LK | 1 |
| Brodie, AM | 1 |
| Goloubeva, OG | 1 |
| Clement, OO | 1 |
| Nanne, IP | 1 |
| Soprano, DR | 1 |
| Njar, VC | 1 |
| Muftuoglu, Y | 1 |
| Mustata, G | 1 |
| Sheng, L | 1 |
| Anderson, PH | 1 |
| Turner, AG | 1 |
| Pishas, KI | 1 |
| Dhatrak, DJ | 1 |
| Gill, PG | 1 |
| Morris, HA | 1 |
| Callen, DF | 1 |
| Lim, YW | 1 |
| Goh, BC | 1 |
| Wang, LZ | 1 |
| Tan, SH | 1 |
| Chuah, BYS | 1 |
| Lim, SE | 1 |
| Iau, P | 1 |
| Buhari, SA | 1 |
| Chan, CW | 1 |
| Sukri, NB | 1 |
| Cordero, MT | 1 |
| Soo, R | 1 |
| Lee, SC | 1 |
| Verlinden, L | 1 |
| Verstuyf, A | 1 |
| Quack, M | 1 |
| Van Camp, M | 1 |
| Van Etten, E | 1 |
| De Clercq, P | 1 |
| Vandewalle, M | 1 |
| Carlberg, C | 1 |
| Bouillon, R | 1 |
| Forgue-Lafitte, ME | 1 |
| Coudray, AM | 1 |
| Fagot, D | 1 |
| Mester, J | 1 |
| Najid, A | 1 |
| Ratinaud, MH | 1 |
| Van Wauwe, JP | 1 |
| Janssen, PA | 1 |
| Shaw, MA | 1 |
| Nicholls, PJ | 1 |
| Smith, HJ | 1 |
| Harris, AL | 1 |
| Cantwell, BM | 1 |
| Dowsett, M | 1 |
| Sonino, N | 1 |
| Namer, M | 1 |
| Khater, R | 1 |
| Frenay, M | 1 |
| Boublil, JL | 1 |
| Feldman, LD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Study of Docetaxel Combined With Ketoconazole in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor[NCT00212095] | Phase 2 | 30 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| [NCT01247467] | 10 participants (Anticipated) | Observational | 2010-08-31 | Active, not recruiting | |||
| Gene Expression Profiles of Breast Cancer Treated With Sequential Adriamycin and Docetaxel in Relation to Tumor Responses[NCT00212082] | Phase 2 | 100 participants | Interventional | 2002-04-30 | Completed | ||
| [NCT01227733] | 0 participants | Observational | 2010-08-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for ketoconazole and Breast Neoplasms
| Article | Year |
|---|---|
Is there a case for P-450 inhibitors in cancer treatment?
Topics: Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Enzym | 1989 |
Aminoglutethimide and ketoconazole: historical perspectives and future prospects.
Topics: Adrenal Gland Neoplasms; Aminoglutethimide; Aromatase Inhibitors; Breast Neoplasms; Fadrozole; Femal | 1988 |
The endocrine effects of ketoconazole.
Topics: Animals; Breast Neoplasms; Cushing Syndrome; Endocrine System Diseases; Female; Hirsutism; Humans; K | 1986 |
1 trial available for ketoconazole and Breast Neoplasms
| Article | Year |
|---|---|
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug | 2010 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug | 2010 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug | 2010 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug | 2010 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug | 2010 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug | 2010 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug | 2010 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug | 2010 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug | 2010 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug | 2010 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug | 2010 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug | 2010 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug | 2010 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug | 2010 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug | 2010 |
Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Docetaxel; Drug | 2010 |
9 other studies available for ketoconazole and Breast Neoplasms
| Article | Year |
|---|---|
Novel retinoic acid metabolism blocking agents endowed with multiple biological activities are efficient growth inhibitors of human breast and prostate cancer cells in vitro and a human breast tumor xenograft in nude mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cricetinae; Cytochrome P-450 Enzyme Inhibitors; Cy | 2004 |
Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19).
Topics: Antineoplastic Agents; Aromatase; Aromatase Inhibitors; Binding Sites; Breast Neoplasms; Computer Si | 2010 |
Identification of vitamin D
Topics: Antineoplastic Agents; Breast; Breast Neoplasms; Calcitriol; Cell Adhesion; Cell Line, Tumor; Cholec | 2016 |
Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D3 responsive elements.
Topics: Adenocarcinoma; Alkynes; Animals; Breast Neoplasms; Calcitriol; Cell Division; Chlorocebus aethiops; | 2001 |
Effects of ketoconazole on the proliferation and cell cycle of human cancer cell lines.
Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Adenocarcinoma; Breast Neoplasms; Cell | 1992 |
Comparative studies of steroidogenesis inhibitors (econazole, ketoconazole) on human breast cancer MCF-7 cell proliferation by growth experiments, thymidine incorporation and flow cytometric DNA analysis.
Topics: Breast Neoplasms; Cell Division; DNA, Neoplasm; Drug Screening Assays, Antitumor; Econazole; Flow Cy | 1991 |
High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer.
Topics: 17-alpha-Hydroxyprogesterone; Aged; Aged, 80 and over; Androstenedione; Breast Neoplasms; Dehydroepi | 1988 |
[High-dose ketoconazole in the treatment of advanced cancer of the breast].
Topics: Breast Neoplasms; Female; Humans; Ketoconazole | 1986 |
Ketoconazole for male metastatic breast cancer.
Topics: Adenocarcinoma; Breast Neoplasms; Humans; Ketoconazole; Male; Middle Aged | 1986 |